Skip to main content

Table 3 Intraoperative, histopathologic, and postoperative data of 188 patients with high-risk localized and locally advanced prostate cancer undergoing RARP

From: Robot-assisted radical prostatectomy in the treatment of patients with clinically high-risk localized and locally advanced prostate cancer: single surgeons functional and oncologic outcomes

Parameters

N = 188

Operative time, median (IQR), minutes

185 (130–260)

Blood loss, median (IQR), ml

200 (150–450)

Blood transfusion

1 (0.5%)

PLND

 

 Extended PLND

170 (90.4%)

 Limited PLND

18 (9.6%)

 Nodal involvement

12 (6.4%)

Complications

 

 Clavien grade I, II

22 (11.7%)

 Clavien grade ≥ III

5 (2.7%)

Pathologic stage

 

 High-risk localized (≤ pT2c)

63 (33.5%)

 High-risk locally advanced

125 (66.5%)

  pT3a

75 (39.9%)

  ≥ pT3b

50 (26.6%)

Pathologic Gleason score

 

 7

81 (43.1%)

 8

74 (39.4%)

  ≥ 9

33 (17.6%)

PSMs

 

 Overall

50 (26.6%)

 In pT2 cancer

16 (8.5%)

 In pT3 cancer

34 (18.1%)

Adjuvant treatment

 

 Overall

63 (33.5%)

 Radiotherapy

25 (13.3%)

 Hormonal therapy

38 (20.2%)

Salvage treatment

 

 Overall

35 (18.6%)

 Radiotherapy

10 (5.3%)

 Hormonal therapy

15 (8.0%)

 Secondary after adjuvant therapy

10 (5.3%)

Follow-up duration, median (IQR), month

66.5 (13–94)

 BCR

42 (22.3%)

 Time to BCR, median (IQR)

10.5 (3.5–26)